Get the Stockscreener App
3.84
5.19%
-0.21
After Hours:
3.89
0.05
+1.30%
Myriad Genetics Inc stock is traded at $3.84, with a volume of 2.52M.
It is down -5.19% in the last 24 hours and down -27.68% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$4.05
Open:
$4.05
24h Volume:
2.52M
Relative Volume:
1.17
Market Cap:
$353.96M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-2.9538
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-17.42%
1M Performance:
-27.68%
6M Performance:
-69.69%
1Y Performance:
-86.27%
1-Day Range:
$3.83
$4.07
1-Week Range:
$3.83
$4.7366
52-Week Range:
$3.8119
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.84 | 373.32M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics secures $200 million credit facility from OrbiMed By Investing.com - Investing.com Canada
Myriad Genetics secures $200 million credit facility from OrbiMed - Investing.com Australia
Myriad Genetics Secures $200 Million Senior Secured Term Loan Facility from OrbiMed - Quiver Quantitative
Myriad Genetics Announces New $200 Million Credit Facility - GlobeNewswire
Myriad Genetics Secures $200 Million Credit Facility with OrbiMed - AInvest
Myriad Genetics Just Secured $200M Strategic Financing: Here's What It Means for Growth - Stock Titan
Is it the right time to buy Myriad Genetics Inc. stockEarnings Report Alerts For Every Investor - jammulinksnews.com
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewswire
Myriad Genetics, Inc. to Host Second Quarter 2025 Earnings Conference Call on August 5, 2025 - Quiver Quantitative
Why Myriad Genetics (MYGN) Shares Are Falling Today - Yahoo Finance
Cancer Biopsy Market Set to Witness Significant Growth - openPR.com
Is Myriad Genetics Inc. Forming a Consolidation BaseOptimized Watchlist With Daily Adjustments Launched - metal.it
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - Yahoo Finance
How strong is Myriad Genetics Inc. company’s balance sheetPost Market Planner That Work - jammulinksnews.com
What is the risk reward ratio of investing in Myriad Genetics Inc. stockTurn market volatility into profit opportunities - jammulinksnews.com
What is the dividend policy of Myriad Genetics Inc. stockInvest smarter and grow your wealth faster - jammulinksnews.com
What catalysts could drive Myriad Genetics Inc. stock higher in 2025Build wealth faster with consistent investment plans - jammulinksnews.com
What makes Myriad Genetics Inc. stock price move sharplyGet exclusive access to expert stock recommendations - jammulinksnews.com
What is Myriad Genetics Inc. company’s growth strategyHigh-profit stock alerts - jammulinksnews.com
What drives Myriad Genetics Inc. stock priceDynamic investment opportunities - PrintWeekIndia
Myriad Genetics Inc. Stock Analysis and ForecastExtraordinary earning power - PrintWeekIndia
Is Myriad Genetics Inc. a good long term investmentTremendous return rates - PrintWeekIndia
What analysts say about Myriad Genetics Inc. stockExplosive earnings growth - Autocar Professional
Insider Sellers Might Regret Selling Myriad Genetics Shares at a Lower Price Than Current Market Value - simplywall.st
Volatile Stocks to Avoid: Williams-Sonoma, Timken, and Myriad Genetics - AInvest
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):